Regeneron Announces Encouraging Topline Phase 2 Data of High-dose aflibercept in Wet Age-related Macular Degeneration

TARRYTOWN, N.Y. , Aug. 24, 2021 /PRNewswire/ — Phase 3 trials in wet AMD and diabetic macular edema fully recruited, with results expected in the second half of 2022 Regeneron Pharmaceuticals, Inc.  (NASDAQ: REGN ) today announced that an ongoing Phase 2 proof-of-concept trial evaluating an


Get every new post delivered right to your inbox.

Original Source